Is Alphabet’s Advertising Business Ex-Growth?: Alphabet
Feb 8, 2023
Google's ad business faced a rare year-over-year decline. Timing couldn't be worse given the hype around language models like OpenAI's ChatGPT and the thought that these new tools could disrupt Google Search. But don't count Google out, as Alphabet dominates Search and AI. We examine the recent and past quarters to understand the current situation and speculate on when Google advertising might recover.
That’s a Wrap for JPM 2023! What are the Key…
Jan 20, 2023
7investing advisor Dana Abramovitz shares several of her key takeaways from the JP Morgan 2023 health care conference.
Seres Therapeutics: A Microbiome Leader With a Huge Upcoming Catalyst
Jan 11, 2023
Seres Therapeutics is a biotech stock for your watch list. 7investing CEO Simon Erickson describes why the pending approval of its flagship drug could be significant for investors.
Move Over Tech, It’s Healthcare’s Week in the Spotlight
Jan 8, 2023
Las Vegas may have been buzzing (literally) with all of the latest and greatest technology at CES this past week, but those of us interested in the health care industry know to save our energy for...
Why Do Companies Pay Dividends?
Dec 9, 2022
Dividends are among the most-beloved aspects of long-term investing. But why do companies pay them in the first place?
Is Online Dating Good Business?
Dec 6, 2022
With romance in the air (and on the TV) during the holidays, we take a look at the business of online-dating.
Enterprise Software: Time To Be Fearful Or Greedy?
Dec 2, 2022
Enterprise software stocks have experienced quite the battering. And it appears there is no end to this shellacking with many earnings reports driving the stocks further down. Is enterprise software...
What Alexa Can Tell Us About The Metaverse
Nov 18, 2022
With the massive layoffs at Amazon, are there some lessons here regarding the latest craze in the metaverse? Anirban weighs in.
dLocal: A Young Payments Business For The Watchlist
Nov 16, 2022
Anirban dove into dLocal's recent Q3 2022 report and explains why the company deserves a spot on your watchlist.
How Should Intel Navigate the Coming Storms?
Nov 6, 2022
Intel is simultaneously looking to expand its production capacity, find design wins in the data center, and maintain good standing with institutions. What path should take priority, and what will...
Why Apple’s Stock Is Beating Microsoft, Alphabet, and Amazon
Nov 4, 2022
Apple generated over $110 billion in free cash flow during its fiscal 2022, up 20% year-over-year. Anirban reviews the company's recently reported Q4 2022 earnings and discusses the road ahead...
Our Top Stock Picks for November 2022
Nov 1, 2022
7investing's November recommendations are now live! Come take a look at the 7 stocks our advisors have chosen as their favorite opportunities in the market this month.
How to Invest in Biotechnology
Oct 27, 2022
7investing's resident biotech PhD shares some valuable lessons about what to look for when investing in this space.
The ABCs of ADRs (and GDRs!)
Oct 26, 2022
Luke Hallard explores the mechanics of when and how to buy a Depositary Receipt.
By Luke Hallard
The “Buy Versus Build” Decision
Oct 23, 2022
The digital world moves quickly. How should companies approach innovation?
Are The iPhone Scuttlebutts Giving You A Migraine?
Oct 19, 2022
Ever since Apple's fall event announced the arrival of the new iPhone 14 and iPhone 14 Pro models, there's constant speculation about the demand or lack thereof for these smartphones. How should we...
Explaining the Stock Market’s Wild Post-CPI Swings
Oct 14, 2022
The market plunged -- and rallied -- after another hotter-than-expected CPI reading this week. Here's what investors need to know.
Premium Special Report
7investing’s Strong Buy Portfolio Update: October 2022
Oct 7, 2022
Welcome to 7investing in October!
Oct 3, 2022
7investing's October recommendations are now live! Come take a look at the 7 stocks our advisors have chosen as their favorite opportunities in the market this month.
DEI in Health Care: More Important than You Think
Sep 30, 2022
Lead Advisor Dana Abramovitz discusses the importance of diversity in clinical trials.
Is It Finally Time for Growth Stocks to Shine Again?
Sep 26, 2022
It might seem crazy given current market volatility, but now might be the perfect time for growth stocks to shine once again.
The Incrementally Innovative Apple
Sep 21, 2022
Incremental innovation is a necessity for success and there's no better proof than Apple's recent "far out" event. Read on for Anirban's take on Apple's recently release iPhones and what this might...
5 Things Investors Should Know About Student Loan Forgiveness
Sep 18, 2022
Finally, we've received clarity on student loan forgiveness and repayment. Here's what investors need to know.
Is Fastly Primed For a Rebound?
Sep 14, 2022
We look into Fastly's Q2 2022 report and try to decipher whether or not now is the time to invest for a rebound.
Is Macro Finally Catching Up With Enterprise Software?
Sep 10, 2022
Anirban checks in on enterprise software behemoths Microsoft & Salesforce to see how they are managing macroeconomic headwinds...
Why Small Modular Nuclear Reactors Could Be The Future of…
Sep 9, 2022
By Luke Hallard